Business
Therapeutics Chief Development Officer Appointment
Therapeutics Chief Development Officer Appointment.
About this update from Avacta Group Plc
[{"type":"text","content":"\n \n \n RNS Number : 7018V\n Avacta Group PLC\n 11 August 2020\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n 11 August 2020\n \n \n Avacta Group plc\n \n \n (\"Avacta\" or \"the Group\" or \"the Company\")\n \n \n \n \n \n Avacta Appoints Therapeutics Chief Development Officer \n \n \n \n \n \n Avacta has appointed Neil Bell, a highly experienced pharmaceutical and biotech industry executive, to lead the ongoing transition to a clinical stage biotech developing innovative cancer therapies \n \n \n Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce the appointment of Neil Bell as Chief Development Officer of Avacta Life Sciences with immediate effect. Neil will be responsible for late stage pre-clinical and early clinical development of Avacta's pipeline of pre|CISION pro-drugs and Affimer immunotherapies.\n \n \n \n \n \n Neil has over 30 years' experience in the drug development industry, having held senior positions in global pharmaceutical companies and innovative biotechs. The early part of his career was spent in clinical development at Eisai and Pfizer before becoming Therapeutic Area Head for Gastroenterology and Neurology at Ipsen. In each of these roles he led numerous Phase I to III clinical studies, gaining significant experience across all facets of drug development; from strategy to pre-clinical development, manufacturing and regulatory, to clinical study design and implementation. \n \n \n \n \n \n In his role as Head of Global Clinical Operations for Teva Pharmaceuticals, Neil led an international team responsible for the delivery of clinical programmes in neurology, autoimmune and oncology therapeutic areas. During this period he contributed to the development of Copaxone achieving leadership in the treatment for multiple sclerosis globally, as well as successfully introducing Azilect to global markets.\n \n \n \n \n \n Following this period at Teva, Neil joined Daichi-Sankyo as Head of Clinical Operations where he led the clinical operations team through early and late stage development activities across cardiovascular, pain and oncology, and was responsible for building an effective drug development organisation in Europe serving the global clinical programmes and leading to the successful global approval...